Trastuzumab in the Treatment of Breast Cancer

被引:175
作者
Maximiano, Sofia [1 ]
Magalhaes, Paulo [1 ,3 ,4 ,5 ]
Guerreiro, Mara Pereira [6 ,7 ]
Morgado, Manuel [1 ,2 ]
机构
[1] Univ Beira Interior, Hlth Sci Res Ctr, CICS UBI, Av Infante D Henrique, Covilha, Portugal
[2] EPE, Cova Beira Hosp Ctr, P-6200251 Quinta Do Alvito, Covilha, Portugal
[3] Univ Coimbra, Fac Pharm, Pharmacol Lab, Polo Ciencias Saude, Coimbra, Portugal
[4] Univ Coimbra, CNC, Ctr Neurosci & Cell Biol, Coimbra, Portugal
[5] Extremadura Univ Hosp & Med Sch, Clin Res Ctr, CICAB, Badajoz, Spain
[6] Lisbon Nursing Sch ESEL, Lisbon, Portugal
[7] Inst Hlth Sci Egas Moniz ISCSEM, CiiEM, Monte De Caparica, Portugal
关键词
PLUS ADJUVANT CHEMOTHERAPY; SUBCUTANEOUS TRASTUZUMAB; MENINGEAL CARCINOMATOSIS; INTRATHECAL TRASTUZUMAB; MONOCLONAL-ANTIBODIES; JOINT ANALYSIS; OPEN-LABEL; RECEPTOR; METAANALYSIS; COMBINATION;
D O I
10.1007/s40259-016-0162-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer (BC) is the most common cancer in women worldwide, and has an undeniable negative impact on public health. The advent of molecular biology and immunotherapy has made targeted therapeutic interventions possible, providing treatments tailored to the individual characteristics of the patient and the disease. The over-expression of human epidermal growth factor receptor (HER) 2 is implicated in the pathophysiology of BC and represents a clinically relevant biomarker for its treatment. Trastuzumab, a recombinant antibody targeting HER2, was the first biological drug approved for the treatment of HER2-positive BC. Although there are currently other anti-HER2 agents available (e.g. pertuzumab and lapatinib), trastuzumab remains the gold standard for treatment of this disease subtype. Nonetheless, concerns have been raised regarding potential cardiotoxicity and treatment resistance. Moreover, several other therapeutic issues remain unclear and have been addressed in an inconsistent way. The current literature lacks a comprehensive review of trastuzumab providing useful information for clinical practice, including pharmacokinetic and pharmacodynamic aspects, its clinical use, existing controversies and future advances. This detailed review of trastuzumab in the pharmacotherapy of BC attempts to fill this gap.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 76 条
[1]   Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients [J].
Ahmad, Sahil ;
Gupta, Sudheer ;
Kumar, Rahul ;
Varshney, Grish C. ;
Raghava, Gajendra P. S. .
SCIENTIFIC REPORTS, 2014, 4
[2]   Trastuzumab in small tumours and in elderly women [J].
Albanell, Joan ;
Ciruelos, Eva M. ;
Lluch, Ana ;
Munoz, Montserrat ;
Rodriguez, Cesar A. .
CANCER TREATMENT REVIEWS, 2014, 40 (01) :41-47
[3]   Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice [J].
Antolin-Novoa, S. ;
Blanco-Campanario, E. ;
Anton, A. ;
Gallegos-Sancho, M. I. ;
Perez-Carrion, R. ;
Pelaez, I. ;
Galan-Brotons, A. ;
de la Cruz-Merino, L. ;
Murias-Rosales, A. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (11) :862-869
[4]   Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].
Arnould, L ;
Gelly, M ;
Penault-Llorca, F ;
Benoit, L ;
Bonnetain, F ;
Migeon, C ;
Cabaret, V ;
Fermeaux, V ;
Bertheau, P ;
Garnier, J ;
Jeannin, JF ;
Coudert, B .
BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267
[5]   Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens? [J].
Azanza, J-R ;
Sadaba, B. ;
Gomez-Guiu, A. .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (05) :370-376
[6]   Trastuzumab Emtansine: First Global Approval [J].
Ballantyne, Anita ;
Dhillon, Sohita .
DRUGS, 2013, 73 (07) :755-765
[7]   Biological therapies in breast cancer: Common toxicities and management strategies [J].
Barroso-Sousa, Romualdo ;
Santana, Iuri A. ;
Testa, Laura ;
Gagliato, Debora de Melo ;
Mano, Max S. .
BREAST, 2013, 22 (06) :1009-1018
[8]   HER-2-Positive breast cancer - Hope beyond trastummab [J].
Bartsch, Rupert ;
Wenzel, Catharina ;
Zielinski, Christoph C. ;
Steger, Guenther G. .
BIODRUGS, 2007, 21 (02) :69-77
[9]   Optimal Management of Brain Metastases from Breast Cancer Issues and Considerations [J].
Bartsch, Rupert ;
Berghoff, Anna S. ;
Preusser, Matthias .
CNS DRUGS, 2013, 27 (02) :121-134
[10]  
Benson JR, 2012, FUTURE ONCOL, V8, P697, DOI [10.2217/fon.12.61, 10.2217/FON.12.61]